Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

E. Cortes, Jörge; H. Heidel, Florian; Hellmann, Andrzej; Fiedler, Walter; Douglas Smith, B.; Robak, Tadeusz; Montesinos, Pau; A. Pollyea, Daniel; DesJardins, Pierre; G. Ottmann, Oliver; Wendy, Weidong; Naveed Shaik, M.; Laird, Alexander; Zeremski, Mirjana; O’Connell, Ashleigh; Chan, Geoffrey; Heuser, Michael

doi:10.1038/s41375-018-0312-9

Public

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Published in Leukemia • Dec 16, 2018

Authors:

Jörge E. Cortes

Florian H. Heidel

Andrzej Hellmann

Abstract

Glasdegib is a Hedgehog pathway inhibitor. This phase II, randomized, open-label, multicenter study (ClinicalTrials.gov, NCT01546038) evaluated the efficacy of glasdegib plus low-dose cytarabine (LDAC) in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome unsuitable for...

Subject

Medicine

Internal medicine

Cytarabine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!